Consensus 99c. Backs FY25 revenue view $900M-$910M, consensus $903.65M. The company said, “Inspire is maintaining full year 2025 revenue guidance to be in the range of $900 million to $910 million, which represents growth of 12% to 13% over full year 2024 revenue of $802.8 million. The company is maintaining its full year 2025 gross margin guidance of 84% to 86%. Inspire anticipates diluted net income per share guidance for the full year 2025 to be in the range of $0.90 to $1.00. This compares to the prior guidance of $0.40 to $.50 per share.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical reports Q3 adjusted EPS 38c, consensus (17c)
- INSP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Inspire Medical’s EURO-STIM Registry: A Long-Term Look at Sleep Apnea Treatment
- Inspire Medical’s New Study: Expanding Horizons for OSA Treatment
- Inspire Medical’s Pediatric Study: A Closer Look at the OSA Treatment Registry